Prabhakar Viswanathan

3.2k total citations
27 papers, 1.8k citations indexed

About

Prabhakar Viswanathan is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Prabhakar Viswanathan has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Cardiology and Cardiovascular Medicine and 7 papers in Molecular Biology. Recurrent topics in Prabhakar Viswanathan's work include Heart Failure Treatment and Management (10 papers), Diabetes Treatment and Management (9 papers) and Hormonal Regulation and Hypertension (6 papers). Prabhakar Viswanathan is often cited by papers focused on Heart Failure Treatment and Management (10 papers), Diabetes Treatment and Management (9 papers) and Hormonal Regulation and Hypertension (6 papers). Prabhakar Viswanathan collaborates with scholars based in United States, United Kingdom and Singapore. Prabhakar Viswanathan's co-authors include Paresh Dandona, Priya Mohanty, Husam Ghanim, Chang Ling Sia, Ajay Chaudhuri, Leigh MacConell, Sanaa Abuaysheh, Xuesong Guan, Ralph A. DeFronzo and Ted Okerson and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Prabhakar Viswanathan

24 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prabhakar Viswanathan United States 15 870 784 434 364 287 27 1.8k
Marisa Passarelli Brazil 27 697 0.8× 469 0.6× 483 1.1× 341 0.9× 268 0.9× 105 1.8k
Kazuhiko Tsutsumi Japan 22 495 0.6× 376 0.5× 276 0.6× 310 0.9× 251 0.9× 60 1.3k
Xianqin Qu Australia 20 639 0.7× 882 1.1× 279 0.6× 631 1.7× 850 3.0× 47 2.3k
Grażyna Wójcicka Poland 23 297 0.3× 409 0.5× 389 0.9× 384 1.1× 307 1.1× 65 1.8k
Elena Fogari Italy 33 1.4k 1.6× 671 0.9× 546 1.3× 355 1.0× 366 1.3× 79 2.6k
Cecilia Morgantini Canada 18 587 0.7× 334 0.4× 443 1.0× 331 0.9× 240 0.8× 29 1.3k
José B. Lopes de Faria Brazil 25 371 0.4× 583 0.7× 205 0.5× 282 0.8× 149 0.5× 55 1.9k
Changting Xiao Canada 30 1.3k 1.5× 773 1.0× 994 2.3× 806 2.2× 491 1.7× 71 2.8k
Vivian Soetikno Indonesia 23 361 0.4× 616 0.8× 165 0.4× 223 0.6× 220 0.8× 67 1.8k
Xueyao Han China 24 882 1.0× 810 1.0× 399 0.9× 398 1.1× 291 1.0× 126 2.0k

Countries citing papers authored by Prabhakar Viswanathan

Since Specialization
Citations

This map shows the geographic impact of Prabhakar Viswanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prabhakar Viswanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prabhakar Viswanathan more than expected).

Fields of papers citing papers by Prabhakar Viswanathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prabhakar Viswanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prabhakar Viswanathan. The network helps show where Prabhakar Viswanathan may publish in the future.

Co-authorship network of co-authors of Prabhakar Viswanathan

This figure shows the co-authorship network connecting the top 25 collaborators of Prabhakar Viswanathan. A scholar is included among the top collaborators of Prabhakar Viswanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prabhakar Viswanathan. Prabhakar Viswanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(7). 1326–1341.
2.
Butt, Jawad H., Alasdair Henderson, Pardeep S. Jhund, et al.. (2025). FINERENONE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: AN ANALYSIS OF FINEARTS-HF. Journal of the American College of Cardiology. 85(12). 1200–1200.
3.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(8). 1444–1458. 1 indexed citations
4.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. The Lancet Diabetes & Endocrinology. 13(2). 107–118. 6 indexed citations
5.
Ostrominski, John W., Rahul Aggarwal, Brian Claggett, et al.. (2024). Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. Journal of Cardiac Failure. 30(9). 1170–1174. 4 indexed citations
6.
Vaduganathan, Muthiah, Brian Claggett, Ian J. Kulac, et al.. (2024). Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 151(2). 149–158. 25 indexed citations
7.
Desai, Akshay S., Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Finerenone in Patients With a Recent Worsening Heart Failure Event. Journal of the American College of Cardiology. 85(2). 106–116. 9 indexed citations
8.
Vaduganathan, Muthiah, Brian Claggett, Carolyn S.P. Lam, et al.. (2024). Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial. European Journal of Heart Failure. 26(6). 1324–1333. 30 indexed citations
9.
Docherty, Kieran F., Alasdair Henderson, Pardeep S. Jhund, et al.. (2024). Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 151(1). 45–58. 16 indexed citations
10.
Vaduganathan, Muthiah, Brian Claggett, Akshay S. Desai, et al.. (2024). Estimated Long-Term Benefits of Finerenone in Heart Failure. JAMA Cardiology. 10(2). 176–176. 5 indexed citations
11.
Bron, Morgan, Annie Guérin, Dominick Latrémouille-Viau, et al.. (2014). Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. Journal of Medical Economics. 17(9). 646–657. 9 indexed citations
12.
Leifke, Eckhard, Himanshu Naik, Jingtao Wu, et al.. (2012). A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes. Clinical Pharmacology & Therapeutics. 92(1). 29–39. 75 indexed citations
13.
Naik, Himanshu, Majid Vakilynejad, Jingtao Wu, et al.. (2011). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers. The Journal of Clinical Pharmacology. 52(7). 1007–1016. 74 indexed citations
14.
Marcinak, John, Prabhakar Viswanathan, Vipin Arora, et al.. (2011). Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs. Clinical Pharmacology & Therapeutics. 91(3). 514–520. 4 indexed citations
15.
Ghanim, Husam, Jay Friedman, Sanaa Abuaysheh, et al.. (2010). Differential Effects of Cream, Glucose, and Orange Juice on Inflammation, Endotoxin, and the Expression of Toll-Like Receptor-4 and Suppressor of Cytokine Signaling-3. Diabetes Care. 33(5). 991–997. 202 indexed citations
16.
Ghanim, Husam, Chang Ling Sia, Kelly Korzeniewski, et al.. (2010). Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. American Journal of Clinical Nutrition. 91(4). 940–949. 245 indexed citations
17.
Dhindsa, Sandeep, et al.. (2008). Relationship of Prostate -Specific Antigen to Age and Testosterone in Men With Type 2 Diabetes Mellitus. Endocrine Practice. 14(8). 1000–1005. 14 indexed citations
18.
Viswanathan, Prabhakar, et al.. (2007). Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin. Endocrine Practice. 13(5). 444–450. 122 indexed citations
19.
Bhatia, Vishal & Prabhakar Viswanathan. (2006). Insulin resistance and PPAR insulin sensitizers.. PubMed. 7(10). 891–7. 38 indexed citations
20.
Viswanathan, Prabhakar. (1999). Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovascular Research. 42(2). 530–542. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marisa Passarelli Breakdown of academic impact, for papers by Kazuhiko Tsutsumi Breakdown of academic impact, for papers by Xianqin Qu Breakdown of academic impact, for papers by Grażyna Wójcicka Breakdown of academic impact, for papers by Elena Fogari Breakdown of academic impact, for papers by Cecilia Morgantini Breakdown of academic impact, for papers by José B. Lopes de Faria Breakdown of academic impact, for papers by Changting Xiao Breakdown of academic impact, for papers by Vivian Soetikno Breakdown of academic impact, for papers by Xueyao Han
Rankless by CCL
2026